|Mr. Alfred F. Altomari||Chairman, Chief Exec. Officer and Pres||733.14k||N/A||58|
|Mr. Scott M. Coiante||CFO & Sr. VP||434.52k||N/A||50|
|Dr. Elizabeth Ijeoma Onyemelukwe Garner M.D., M.P.H.||Chief Medical Officer and Sr. VP||532.43k||N/A||49|
|Mr. Geoffrey P. Gilmore||Gen. Counsel||N/A||N/A||51|
|Ms. Renee E. Selman||Chief Commercial Officer||N/A||N/A||55|
Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Agile Therapeutics, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 7.